In Stock
Cagrilintide is a long-acting amylin analogue peptide developed by Novo Nordisk to treat obesity and type 2 diabetes by mimicking natural amylin to reduce appetite and delay gastric emptying. Often studied in combination with semaglutide (CagriSema), it has shown significant, dose-dependent weight loss and is currently in Phase 3 trials.
Cagrilintide is a long-acting amylin analogue peptide developed by Novo Nordisk to treat obesity and type 2 diabetes by mimicking natural amylin to reduce appetite and delay gastric emptying. Often studied in combination with semaglutide (CagriSema), it has shown significant, dose-dependent weight loss and is currently in Phase 3 trials.
Office Hours: Mon–Sat, 9:00 AM–5:00 PM (By Appointment)
Online Services: Available 24/7
13791 E Rice Place #205 Aurora, CO 80015
Reviews
There are no reviews yet.